Background Malignant hyperthermia (MH), a metabolic myopathy triggered by volatile anesthetics and depolarizing muscle relaxants, is a potentially lethal complication of general anesthesia in susceptible patients. The implementation of modern inhalation anesthetics that research indicates as less potent trigger substances and the recommended limitations of succinylcholine use, suggests there may be considerable decline of fulminant MH cases. In the presented study, the authors analyzed suspected MH episodes during general anesthesia of patients that were referred to the Wuerzburg MH unit between 2007 and 2011, assuming that MH is still a relevant anesthetic problem in our days. Methods With approval of the local ethics committee da...
Malignant Hyperthermia (MH) is a rare, hereditary, life-threatening disease triggered by volatile an...
Malignant hyperthermia manifests clinically as a hypermetabolic crisis when a malignant hyperthermia...
The anaesthetic records of 61 patients who had experienced adverse reactions thought to be malignant...
Malignant Hyperthermia (MH), is a rare emergency that happened during General Anesthesia. In Albania...
Copyright © 2013 Frank Schuster et al.This is an open access article distributed under the Creative ...
Abstract Background and objectives: Malignant hyperthermia is an autosomal dominant hypermetabolic ...
Malignant hyperthermia is a subclinical myopathy, usually triggered by anesthetics and associated wi...
Abstract Introduction Malignant hyperthermia is an autosomal dominant pharmacogenetic disorder, cha...
Malignant hyperthermia is a subclinical myopathy in which general anesthesia triggers an uncontrolla...
Malignant hyperthermia is rare inherited disorder in our part of the world; there are only few cases...
Introduction Malignant Hyperthermia (MH) is an inherited hypermetabolic syndrome triggered by exposu...
Malignant hyperthermia (MH) can develop after contact with volatile anesthetics (halothane, enfluran...
Copyright © 2014 Michihiro Sakai et al.This is an open access article distributed under theCreative ...
Preoperative evaluation of the patients scheduled for ambulatory surgery is of great importance in r...
Malignant hyperthermia (MH) is a rare and life-threatening pharmacogenetic disorder triggered by vol...
Malignant Hyperthermia (MH) is a rare, hereditary, life-threatening disease triggered by volatile an...
Malignant hyperthermia manifests clinically as a hypermetabolic crisis when a malignant hyperthermia...
The anaesthetic records of 61 patients who had experienced adverse reactions thought to be malignant...
Malignant Hyperthermia (MH), is a rare emergency that happened during General Anesthesia. In Albania...
Copyright © 2013 Frank Schuster et al.This is an open access article distributed under the Creative ...
Abstract Background and objectives: Malignant hyperthermia is an autosomal dominant hypermetabolic ...
Malignant hyperthermia is a subclinical myopathy, usually triggered by anesthetics and associated wi...
Abstract Introduction Malignant hyperthermia is an autosomal dominant pharmacogenetic disorder, cha...
Malignant hyperthermia is a subclinical myopathy in which general anesthesia triggers an uncontrolla...
Malignant hyperthermia is rare inherited disorder in our part of the world; there are only few cases...
Introduction Malignant Hyperthermia (MH) is an inherited hypermetabolic syndrome triggered by exposu...
Malignant hyperthermia (MH) can develop after contact with volatile anesthetics (halothane, enfluran...
Copyright © 2014 Michihiro Sakai et al.This is an open access article distributed under theCreative ...
Preoperative evaluation of the patients scheduled for ambulatory surgery is of great importance in r...
Malignant hyperthermia (MH) is a rare and life-threatening pharmacogenetic disorder triggered by vol...
Malignant Hyperthermia (MH) is a rare, hereditary, life-threatening disease triggered by volatile an...
Malignant hyperthermia manifests clinically as a hypermetabolic crisis when a malignant hyperthermia...
The anaesthetic records of 61 patients who had experienced adverse reactions thought to be malignant...